IRIS
LADETTO, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.149
NA - Nord America 2.769
AS - Asia 2.642
SA - Sud America 771
AF - Africa 114
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 3
Totale 9.457
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.664
IE - Irlanda 1.348
SG - Singapore 1.154
HK - Hong Kong 645
BR - Brasile 617
RU - Federazione Russa 549
VN - Vietnam 359
SE - Svezia 317
DE - Germania 245
UA - Ucraina 242
CN - Cina 209
IT - Italia 204
FI - Finlandia 64
BJ - Benin 59
GB - Regno Unito 59
IN - India 57
AR - Argentina 56
CA - Canada 50
ID - Indonesia 48
MX - Messico 39
EC - Ecuador 37
KR - Corea 33
BD - Bangladesh 26
JP - Giappone 21
ZA - Sudafrica 21
PL - Polonia 19
CO - Colombia 18
NL - Olanda 18
FR - Francia 17
AT - Austria 16
IQ - Iraq 15
EG - Egitto 13
CL - Cile 12
LT - Lituania 10
PE - Perù 10
PK - Pakistan 10
TR - Turchia 10
CZ - Repubblica Ceca 9
ES - Italia 9
IR - Iran 9
PY - Paraguay 9
AE - Emirati Arabi Uniti 8
UZ - Uzbekistan 8
VE - Venezuela 8
KE - Kenya 7
EU - Europa 6
MA - Marocco 5
SA - Arabia Saudita 5
AU - Australia 3
BE - Belgio 3
BO - Bolivia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
GR - Grecia 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
TN - Tunisia 3
BN - Brunei Darussalam 2
EE - Estonia 2
JM - Giamaica 2
KW - Kuwait 2
KZ - Kazakistan 2
LB - Libano 2
OM - Oman 2
PA - Panama 2
SI - Slovenia 2
SV - El Salvador 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CH - Svizzera 1
CI - Costa d'Avorio 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
LK - Sri Lanka 1
LU - Lussemburgo 1
ME - Montenegro 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
YE - Yemen 1
Totale 9.457
Salva come PNG Salva come JPEG
Città #
Dublin 1.344
Hong Kong 645
Jacksonville 296
Singapore 293
Ashburn 197
Moscow 196
Wilmington 195
Lawrence 174
Princeton 174
San Mateo 145
Chandler 130
Ho Chi Minh City 130
Los Angeles 108
Beijing 90
Dearborn 84
Buffalo 73
Hanoi 68
Dallas 65
Cotonou 59
São Paulo 51
Redondo Beach 48
New York 43
Seoul 33
Novara 28
Piemonte 28
Boardman 27
Bremen 26
Rio de Janeiro 25
Houston 24
Ann Arbor 23
Helsinki 22
Haiphong 21
Tokyo 21
Fairfield 19
Montreal 18
Toronto 18
Warsaw 18
Brasília 16
Brooklyn 16
Falkenstein 16
Denver 15
Norwalk 15
Andover 14
Da Nang 14
Des Moines 14
Quito 14
Chennai 13
Nuremberg 13
Santa Clara 13
Stockholm 13
Tianjin 13
Woodbridge 13
Atlanta 12
Frankfurt am Main 12
Johannesburg 12
London 12
Milan 12
Orem 12
Poplar 12
Mexico City 11
Curitiba 10
Thái Bình 10
Vienna 10
Biên Hòa 9
Boston 9
Brno 9
Munich 9
Porto Alegre 9
Querétaro 9
Turin 9
Amsterdam 8
Jakarta 8
Mülheim 8
Ninh Bình 8
Phoenix 8
Seattle 8
Tashkent 8
Campinas 7
Guayaquil 7
Hải Dương 7
Menlo Park 7
Mumbai 7
Sorocaba 7
Assago 6
Belo Horizonte 6
Florianópolis 6
Guangzhou 6
Lima 6
Lấp Vò 6
Salvador 6
Santo André 6
Asunción 5
Bologna 5
Buenos Aires 5
Chicago 5
Goiânia 5
Grafing 5
Hefei 5
Juiz de Fora 5
Magé 5
Totale 5.550
Salva come PNG Salva come JPEG
Nome #
STAble: A novel approach to de novo assembly of RNA-seq data and its application in a metabolic model network based metatranscriptomic workflow 113
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up 105
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 104
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 101
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 96
MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia 95
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes 91
Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients 89
Comparison of different DNA extraction methods from peripheral blood cells: advices from the Fondazione Italiana Linfomi - MRD Network. 88
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 87
Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation 86
COMPARISON OF TWO REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION STRATEGIES FOR MINIMAL RESIDUAL DISEASE EVALUATION IN LYMPHOPROLIFERATIVE DISORDERS: CORRELATION BETWEEN IMMUNOGLOBULIN GENE MUTATION LOAD AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION PERFORMANCE 84
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 84
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 82
Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies 81
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib 80
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 80
CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia 79
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment 79
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi 78
Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients 77
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib 76
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 76
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 72
Genetic and phenotypic attributes of splenic marginal zone lymphoma 72
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 70
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 69
THE HOST GENETIC BACKGROUND OF DNA REPAIR MECHANISMS IS AN INDEPENDENT PREDICTOR OF PROGRESSION AND OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA 68
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 68
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 65
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 65
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 64
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 64
Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 63
Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I-II follicular lymphoma: Results of a multicenter study 63
Controversies in the treatment of follicular lymphoma 60
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 60
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients 59
Droplet Digital PCR Assay for MYD88L265P 59
Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione italiana linfomi MRD network 59
DEL(13q14) LENGTH MATTERS: AN INTEGRATED ANALYSIS OF GENOMIC, FISH AND CLINICAL DATA IN 169 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH 13q DELETION ALONE OR NORMAL KARYOTYPE 58
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 58
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 57
LOW CD49d AND LONG TELOMERE IDENTIFY A CHRONIC LYMPHOCYTIC LEUKEMIA SUBSET WITH HIGHLY FAVOURABLE OUTCOME 56
A Single-Center Pilot Prospective Study of Topical Application of Platelet-Derived Eye Drops for Patients with Ocular Chronic Graft-versus-Host Disease 56
The adulthood of MRD detection in MCL 56
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 55
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma 55
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes 54
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. 54
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors 54
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial 54
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 53
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 53
Organizational determinants of hospital stay: establishing the basis of a widespread action on more efficient pathways in medical units 52
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests 52
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 51
EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma 51
Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study 51
The black swan: a case of central nervous system graft-versus-host disease 50
TWO MAIN GENETIC PATHWAYS LEAD TO THE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO RICHTER SYNDROME 50
Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network 50
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 50
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias 50
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 50
Pharmacotherapy considerations for patients who develop acute kidney injury during cancer therapy 49
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients 49
LENALIDOMIDE PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE AND RITUXIMAB IS SAFE AND EFFECTIVE IN UNTREATED, ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE I STUDY BY THE FONDAZIONE ITALIANA LINFOMI 49
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL) 49
Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice 48
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 48
Spontaneous splenic rupture during induction therapy in acute myeloid leukemia: An unusual case 48
EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas 47
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma 47
The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma 47
CAR-T therapy: the role of the hematopoietic stem cell processing laboratory 46
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial 46
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission 46
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 46
PCR-detectable non-neoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis, but rare in subjects treated with chemotherapy 46
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 46
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial 45
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 45
Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma 45
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 45
High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity 45
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia 44
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 44
Minimal Residual Disease in Mantle Cell Lymphoma: Methods and Clinical Significance 44
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 44
Home management of hematological patients requiring hospital admission 44
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 44
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapse/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase 3 trial 44
The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma 43
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 43
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial 43
Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 43
Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 43
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft 43
ESMO consensus conference on Malignant lymphoma: Management of ‘ultra-high-risk’ patients 43
Totale 6.032
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.704
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.704
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021525 0 0 0 0 0 5 100 88 159 6 158 9
2021/2022794 4 20 143 55 47 0 16 16 81 13 172 227
2022/20231.966 179 37 76 18 69 123 41 93 1.251 8 50 21
2023/2024706 17 29 30 12 160 5 176 10 6 16 38 207
2024/20252.233 45 7 41 14 22 217 152 119 805 391 65 355
2025/20262.877 165 212 578 1.113 537 272 0 0 0 0 0 0
Totale 9.733